Session » Vasculitis Poster I: Large Vessel Vasculitis

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 781

A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 799

Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 798

Altered Phenotype of Platelets and Neutrophils Toward Neutrophil-Platelet Interaction in Circulation of Small and Large Vessel Vasuculitis

9:00AM-11:00AM: Abstract Number: 791

Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography

9:00AM-11:00AM: Abstract Number: 808

Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort

9:00AM-11:00AM: Abstract Number: 779

Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)

9:00AM-11:00AM: Abstract Number: 807

B Cells in Giant Cell Arteritis: a Novel Target for Treatment?

9:00AM-11:00AM: Abstract Number: 803

Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 795

Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan

9:00AM-11:00AM: Abstract Number: 814

Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides

9:00AM-11:00AM: Abstract Number: 816

Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab

9:00AM-11:00AM: Abstract Number: 818

Correlation between the Routine Assessment of Patient Index Data (RAPID3) and Inflammatory Markers in Patients with PMR

9:00AM-11:00AM: Abstract Number: 784

Damage and Predictors of Damage in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 777

Differences between Temporal Artery Biopsy-Positive and Biopsy-Negative Giant Cell Arteritis: A Comparative Cohort Study

9:00AM-11:00AM: Abstract Number: 821

Discrepancies between Clinical- and Imaging-Based Assessments of Disease Activity in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 806

Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database

9:00AM-11:00AM: Abstract Number: 783

European League Against Rheumatisms Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice

9:00AM-11:00AM: Abstract Number: 817

Extension of Affected Vascular Territories in Secondary Aortitis Is Associated to Different Clinical Subtypes?

9:00AM-11:00AM: Abstract Number: 792

Glucocorticoid Use and Adverse Events in Patients with Polymyalgia Rheumatica in a Contemporary Population-Based Cohort

9:00AM-11:00AM: Abstract Number: 815

Incidence in Large Vessel GCA in Northern Italy during a 11-Year Period

9:00AM-11:00AM: Abstract Number: 813

Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 824

Long Term Efficacy and Safety of Intravenous and Subcutaneous Biologics in Large Vessels Vasculitis: 21 Patients Belonging to a Single Italian Center from 2011 to 2017

9:00AM-11:00AM: Abstract Number: 785

Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 789

Markers of Inflammation and Patient-Reported Measures As Predictors of Relapse in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 788

Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 800

Measurement of Serum Cytokines during the Apparent Remission State of Takayasu Arteritis – What Do Cytokines Tell Us?

9:00AM-11:00AM: Abstract Number: 793

Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be

9:00AM-11:00AM: Abstract Number: 812

Mortality Risk and Cause-Specific Mortality in Polymyalgia Rheumatica: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 794

Negative Temporal Artery Biopsies: Comparison between Biopsy-Negative GCA and Non-GCA Patients

9:00AM-11:00AM: Abstract Number: 801

PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?

9:00AM-11:00AM: Abstract Number: 790

Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids

9:00AM-11:00AM: Abstract Number: 796

Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases

9:00AM-11:00AM: Abstract Number: 809

Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study

9:00AM-11:00AM: Abstract Number: 787

Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 820

Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 825

Radiological Disease Activity Is the Major Determinant for Physicians While Deciding Active Disease in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 819

Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 778

Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations

9:00AM-11:00AM: Abstract Number: 823

Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample

9:00AM-11:00AM: Abstract Number: 810

Sensitivity of Temporal Artery Biopsy in Giant Cell Arteritis: Systematic Literature Review and Meta-Analysis of Clinical Data

9:00AM-11:00AM: Abstract Number: 802

Sensorineural Hearing Loss in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 805

Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 782

Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 780

Short and Long-Term Follow-up with Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 49 Patients of Clinical Practice

9:00AM-11:00AM: Abstract Number: 786

Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 797

Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases

9:00AM-11:00AM: Abstract Number: 804

The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate

9:00AM-11:00AM: Abstract Number: 822

The Incidence Rate of Deep Vein Thrombosis and/or Pulmonary Embolism in Patients with Giant Cell Arteritis – Single Center Observational Study

9:00AM-11:00AM: Abstract Number: 811

The Presence of Giant Cells in the Temporal Artery Biopsy Is Associated with Reduced Risk of Future Large Vessel Involvement in Patients with Biopsy-Proven Giant Cell Arteritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].